10.5281/zenedo.15960797

NEXUS KNOWLEDGE PUBLICATION

https://nknpub.com/index.php/1

ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS

ISBN Number- 978-81-985724-7-9



Published By – Nexus Knowledge Publication

(Imprint of AKT Multitask Consultancy)

Bilaspur, Chhattisgarh, India, 495006

www.aktmultitask.com

Chapter- 10

APPLICATIONS OF PHARMACOKINETICS IN BIOTECHNOLOGICAL PRODUCTS

DR. RAGHAV DIXIT
Assistant Professor
School of Pharmaceutical Sciences, Swami Rama Himalayan University,
Jolly Grant, Dehradun, 248016, India
Email: raghavdixitphd1985@gmail.com

DEEPTHI O
Assistant Professor
National College of Pharmacy,
Manassery,Kozhikode, Kerala, 673602
Email: deepthi10000@gmail.com

DR. YERIKALA RAMESH
Professor and HOD
Ratnam Institute of Pharmacy,
Pidathapolour Village and Post,
Muthukur Mandal, SPSR Nellore
Pin: 524 346
Email: yrameshpharma@gmail.com

DR. PREM SHANKAR GUPTA
Associate Professor
Department of Pharmaceutics, Teerthanker Mahaveer College of Pharmacy,
Teerthanker
Mahaveer University, Moradabad, Uttar Pradesh
Pin: 244001
Email: premsgupta.rs.bme17@iitbhu.ac.in

DR MEESALA SUDHAKAR
Guest faculty, Atal Bihari Vajpayee Viswa Vidyalaya,
Koni Bilaspur (C.G.),495009,
Email: sudhakarmeesala55@gmail.com

10.5281/zenedo.15960797

Chapter 10….

APPLICATIONS OF PHARMACOKINETICS IN BIOTECHNOLOGICAL PRODUCTS

DR. RAGHAV DIXIT
Assistant Professor
School of Pharmaceutical Sciences, Swami Rama Himalayan University,
Jolly Grant, Dehradun, 248016, India
Email: raghavdixitphd1985@gmail.com

DEEPTHI O
Assistant Professor
National College of Pharmacy,
Manassery,Kozhikode, Kerala, 673602
Email: deepthi10000@gmail.com

DR. YERIKALA RAMESH
PROFESSOR AND HOD
RATNAM INSTITUTE OF PHARMACY, PIDATHAPOLOUR VILLAGE AND POST,
MUTHUKUR MANDAL, SPSR NELLORE
Pin: 524 346
Email: yrameshpharma@gmail.com

DR. PREM SHANKAR GUPTA
Associate Professor
Department of Pharmaceutics, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh
Pin: 244001
Email: premsgupta.rs.bme17@iitbhu.ac.in

DR MEESALA SUDHAKAR
Guest faculty, Atal Bihari Vajpayee Viswa Vidyalaya,
Koni Bilaspur (C.G.),495009,
Email: sudhakarmeesala55@gmail.com

For biotechnological products to be developed, optimized, and used in clinical settings, pharmacokinetics (PK) is essential. A thorough grasp of biopharmaceuticals' pharmacokinetic characteristics is now even more crucial as they continue to transform medical care. Because of their complexity and biological makeup, biotechnology medications such as gene therapies, monoclonal antibodies, immunotherapies, and oligonucleotides necessitate a special method of pharmacokinetic study. The pharmacokinetic behavior of these treatments is very different from that of conventional small-molecule medications, and they are frequently given parenterally. These complicated medications' interactions with the body can affect their ADME (absorption, distribution, metabolism, and excretion), which can affect their safety and effectiveness profiles [1].

This chapter explores the many ways that pharmacokinetics is used in the biotechnology industry. We examine the pharmacokinetic concepts of gene therapies, a quickly developing category of biotechnological products that directly alter the patient's genome to treat hereditary illnesses. We also look at how pharmacokinetics plays a part in immunotherapy and vaccines, two fields that have grown significantly because of their promise to cure infectious diseases and cancer [2]. The chapter also discusses the difficulties in medication development and the distinct pharmacokinetic properties of oligonucleotides and other biotech products. Last but not least, the pharmacodynamics of biotechnology medications are examined in light of the body's reaction to these innovative treatments, providing information about their therapeutic potential and a framework for optimizing them in clinical settings. The chapter emphasizes the vital role that pharmacokinetics plays in expanding the therapeutic potential of biotechnological products through this thorough analysis.

10.1PHARMACOKINETICS OF GENE THERAPIES

Gene therapies are cutting-edge medical interventions intended to modify, replace, or repair damaged genes that cause illness. Gene therapies, as opposed to conventional medications, treat or prevent disease at the genetic level by introducing genetic material into a patient's cells. Understanding the pharmacokinetics (PK) of these treatments is made more difficult by this novel method.

10.5281/zenedo.15960797



Figure 1: Gene Therapy: A Pharmacokinetics

The processes by which the therapeutic genetic material is absorbed, distributed, metabolized, and eliminated inside the body are all included in the pharmacokinetics of gene therapies. Since these procedures entail the administration of nucleic acids (DNA or RNA), which must be effectively delivered to the target cells and tissues in order to exert their therapeutic impact, they diverge greatly from conventional medications [3]. The particular pharmacokinetic characteristics of gene treatments as well as the variables affecting their safety and effectiveness are covered in this section.

10.1.1 Delivery Methods and Absorption

A key component of gene therapy is the transfer of genetic material, and the effectiveness of this process greatly depends on the delivery method employed. Because nucleic acids are complicated and difficult to pass through cell membranes, gene therapies require more complex delivery systems than small molecule medications, which can be given orally or by injection. In addition to ensuring that the genetic material reaches its intended cells, the delivery mechanism must shield it against enzymatic and immune system breakdown [4].

- **Vector-Based Delivery Systems**

Gene therapies typically rely on vector-based systems for the delivery of genetic material. These systems can be broadly categorized into viral vectors and non-viral vectors.

Viral Vectors

Among the most often used methods for gene delivery are viral vectors, including adenoviruses, lentiviruses, retroviruses, and adeno-associated viruses (AAVs). These viruses are perfect for introducing genetic material into human cells because they have developed the ability to transduce cells effectively. By attaching to particular cell surface receptors and promoting internalization through endocytosis, viral vectors take use of viruses' innate capacity to infiltrate cells. The viral genome can either stay episomal (living outside of the host genome) or integrate into the host's genome once it has entered the cell.

High transfection effectiveness, or the capacity to transfer genetic material into a significant portion of the target cells, is the main benefit of viral vectors. For instance, because AAV vectors may infect non-dividing cells and have a lower immunogenic profile than other viral vectors like adenoviruses, they are especially preferred in the treatment of hemophilia and muscular dystrophy.

Viral vectors do, however, have certain disadvantages. An immune response that neutralizes the viral vector before it can deliver its genetic payload may result from the immune system's recognition of the vectors as foreign substances. Patients may acquire antibodies against the viral vector, which would decrease the effectiveness of subsequent dosages. This is a serious problem, especially for recurrent administrations. Researchers are creating altered viral vectors that lower immune recognition while preserving high transfection efficiency in order to overcome these difficulties [5].

Non-Viral Vectors

A safer substitute for viral vectors is non-viral ones, such as liposomes, polymers, and nanoparticles. These technologies encapsulate the genetic material in synthetic or lipid-based polymeric carriers. Lipid bilayer vesicles called liposomes have the ability to encapsulate both DNA and RNA, preventing their breakdown and promoting cell membrane fusion, which aids in the direct delivery of genetic material into the cell.

It is also possible to create nanoparticles, which are frequently made of biodegradable materials, to encapsulate and safeguard genetic material. Since non-viral vectors are less likely than viral vectors to elicit an immune response, they are a desirable alternative for long-term therapies. Non-viral vectors' efficacy in some applications may be constrained by their generally lower transfection efficiency when compared to viral vectors. Furthermore, the delivery system could struggle to effectively target particular tissues or get past biological

10.5281/zenedo.15960797

barriers like the blood-brain barrier (BBB) in cases of illnesses affecting the central nervous system (CNS).

- **Routes of Administration**

Gene therapies can be delivered using a variety of administration routes, each with its specific challenges and advantages.

Systemic Administration (Intravenous Injection)

Gene therapy products are frequently given via intravenous (IV) injection when systemic administration is necessary. The genetic material can enter the bloodstream and travel throughout the body through this pathway. After entering the bloodstream, the delivery method—whether viral or non-viral—must pass through a number of biological obstacles in order to get to the intended tissues. These obstacles include the requirement to get through the target cell's membrane, extracellular breakdown by enzymes, and immunological detection. The quantity of therapeutic material available for gene delivery may be diminished in systemic distribution if the gene therapy product is additionally cleared by the liver, spleen, or other elements of the mononuclear phagocyte system (MPS).

The vector must be able to pass through the bloodstream and not be quickly eliminated by immune cells or other bodily parts in order for systemic distribution to be successful. In certain situations, the vector can be altered to have a longer circulation duration or to avoid immune detection, which can increase the effectiveness of gene delivery.

Local Administration

Gene therapies can sometimes be delivered straight to the target tissue. This is especially important for treating diseases that are specialized to a given location, such liver, muscle, or retinal ailments. For example, intravitreal injections are used to treat retinal diseases like Leber congenital amaurosis, whereas direct injection into muscle tissue has been utilized in studies for muscular dystrophy.

By concentrating the therapeutic genetic material at the intended location, local administration can potentially maximize the therapeutic effect while reducing off-target effects in other tissues. Nevertheless, there are still issues with guaranteeing that the vector is distributed uniformly across the target tissue and successfully transfecting the appropriate cells.

10.1.2 Biological Barriers and Overcoming Challenges

Regardless of the route of administration, gene therapies face numerous **biological barriers** that can hinder the efficient delivery and absorption of genetic material. These include:

- **Immune Response**: An immunological response can be triggered by both viral and non-viral vectors. When it comes to viral vectors, the immune system may identify the vector as alien, leading to either a cellular immune reaction (T-cell activation) or a humoral immunological response (antibody generation), both of which might lessen the efficacy of the treatment. Although to a lesser extent, the immune response can still happen in non-viral vectors.
- **Extracellular Degradation**: Bloodstream enzymes like ribonucleases can quickly break down genetic material, particularly if it is RNA-based. As a result, therapeutic gene material may be lost before it reaches the intended cells.
- **Cellular Uptake**: The vector must be able to enter the target cells even if it makes it to the target tissues. Cell surface receptors, the effectiveness of endocytosis, and the vector's membrane permeability are some of the variables that affect the pace of cellular uptake and, in turn, the therapeutic result.

One important field of research in the creation of gene treatments is overcoming these obstacles. Techniques include encasing genetic material in lipid-based systems that shield it from extracellular breakdown, altering the surface characteristics of nanoparticles to improve cell absorption, and PEGylation (the attachment of polyethylene glycol to vectors) to avoid immune detection.

10.1.3 Distribution and Tissue Penetration

A key factor in determining the effectiveness of gene treatments is their distribution and tissue penetration. The effectiveness of the treatment is greatly impacted by the gene therapy products' capacity to reach the target cells and tissues once they are injected directly into particular tissues or given into the circulation. Gene therapies necessitate precision delivery to specific tissues where the therapeutic impact can occur, in contrast to conventional medications, which are typically made to circulate in the bloodstream and interact with a variety of tissues. With an emphasis on vector types, targeting tactics, and getting past biological barriers, this section goes into detail into the variables affecting the distribution and tissue penetration of gene therapy products [6].

- **Influence of Vector Size, Charge, and Composition**

The distribution and penetration of the treatment into target tissues are significantly influenced by the vector that is employed to transfer the genetic material. The two main categories of gene

therapy vectors are non-viral (such as liposomes, nanoparticles, and polyplexes) and viral (such as lentiviruses, adenoviral vectors, and adeno-associated viruses [AAVs]).

- **Size**: The vector's capacity to enter cells and pierce tissues is influenced by its size. Although tissue penetration is often better with smaller vectors, stability and effective gene delivery may suffer as a result. Though they may have a harder time spreading through tissues, larger vectors—like viral vectors—can infect target cells more effectively once they get there.
- **Charge**: The vector's interaction with cell membranes is also influenced by its surface charge. For instance, positively charged vectors, also known as cationic vectors, can help with cellular uptake by facilitating the electrostatic contact with negatively charged cell membranes. But too much positive charge might cause aggregation, which lowers delivery efficiency. In order to reduce aggregation and improve stability, neutral or slightly negative charges are frequently favored.
- **Composition**: Both the vector's stability and its capacity to reach the target location are significantly influenced by its composition. Adeno-associated virus (AAV)-based viral vectors are very effective at transducing particular tissues. For instance, AAVs are perfect for treating conditions like hemophilia and muscular dystrophy because of their innate predilection for liver, muscle, and retinal tissues. The type of tissue that the vector (a particular virus variation) preferentially targets can be determined by its serotype. However, immunogenicity—the ability of the body's immune system to identify viral components as foreign and generate an immune reaction against them—often limits the efficiency of viral vectors. The overall efficacy of the therapy may be diminished if this immune reaction leads the body to eliminate the vector before it can transfer the therapeutic gene.

➢ **Viral Vectors and Targeted Tissue Delivery**

Viral vectors are the most widely used delivery systems in gene therapy due to their ability to efficiently deliver genetic material into cells. However, one of the key limitations is the narrow targeting specificity. Different viral vectors have varying preferences for specific tissues, which can be exploited to enhance therapeutic targeting. For example:

- **AAVs**: Because of their low immunogenicity and capacity to effectively transduce a variety of cell types, such as muscle, liver, and retinal cells, adeno-associated viruses are among the most widely utilized vectors in gene therapy. Because of this, AAVs are

perfect for treating conditions like hemophilia, muscular dystrophy, and retinal degenerative disorders. Targeting to particular tissues can be further improved by using various AAV serotypes. The immune system may quickly remove the vector from the body after repeated injection, hence problems like neutralizing antibodies against these viruses can reduce their efficacy.

- **Lentiviruses**: A subclass of retroviruses known as lentiviruses is also employed in gene therapy, specifically for hematopoietic stem cell gene therapy and HIV-related treatments. The therapeutic gene may express itself for a long time as a result of these vectors' capacity to incorporate genetic material into the host cell's DNA. Lentiviruses' usefulness in non-dividing tissues is constrained by their propensity to target actively dividing cells.

Since the immune system perceives the viral particles as alien substances and launches an attack, viral vectors are frequently linked to the issue of immunogenicity despite their effectiveness. Because pre-existing immunity against the viral vector may lessen the effectiveness of successive doses, this can restrict the recurrent delivery of viral-based gene treatments.

➢ **Non-Viral Vectors and Tissue Penetration**

Liposomes, polymeric nanoparticles, and lipid nanoparticles are examples of non-viral vectors that are less immunogenic than viral vectors. It is possible to optimize these systems' capacity to transfer genetic information into particular tissues while lowering the immunological response. Applications where gene integration is not necessary or where pre-existing immunity may render viral vectors ineffective frequently employ non-viral vectors.

Because non-viral vectors are less immunogenic, they are safer to employ repeatedly. However, their capacity to target certain tissues is often poorer, and they are frequently less effective at transfecting cells than viral vectors. Researchers are creating sophisticated methods to improve the targeting specificity of non-viral vectors in order to get over this restriction. Among these tactics are:

- **Surface modification**: Targeting ligands, such as peptides or antibodies that bind to particular cell receptors, can be added to liposomes or nanoparticles. For instance, adding a targeting peptide to the surface of nanoparticles can improve tissue specificity by increasing the uptake of the particles by cells that express the relevant receptor.

10.5281/zenedo.15960797

- **Size optimization**: Non-viral vectors' capacity to enter tissues can be enhanced by varying their size. Although smaller particles may be removed from the bloodstream more quickly, they have a tendency to enter tissues more readily. Even though they are more stable in circulation, larger particles could have trouble passing through tissue barriers.

➢ **Overcoming Biological Barriers**

Gene therapy products must not only reach the target tissues but also penetrate cellular barriers to effectively deliver the genetic material. A major challenge in the distribution of gene therapies is the presence of biological barriers, including:

- **Blood-brain barrier (BBB)**: Delivering gene therapies to the brain is made extremely difficult by the BBB. The majority of therapeutic medicines cannot enter the central nervous system due to the BBB's strong endothelial cell connections. Treating neurodegenerative conditions like Parkinson's disease, Alzheimer's disease, and spinal muscular atrophy requires overcoming the blood-brain barrier. To enhance the delivery of gene therapies to the brain, researchers are investigating cutting-edge techniques like the intranasal delivery of nanoparticles or the use of viral vectors designed to cross the blood-brain barrier.
- **Retinal barrier**: The blood-retina barrier and the retinal pigment epithelium are two major obstacles in ocular gene therapy. Vectors that can pass through these barriers without harming delicate eye tissues are necessary for the effective transport of genetic material to the retina for the treatment of diseases like Leber congenital amaurosis or retinal degeneration.
- **Tumor tissue barriers**: The tumor microenvironment may make it more difficult for gene therapies that target solid tumors to deliver genetic material to tumor cells. The vasculature of tumor tissues is frequently uneven, which makes it challenging for gene treatments to deeply penetrate the tumor bulk. To increase tumor-targeting efficiency, methods like creating nanoparticles that can pass through the tumor stroma or using tumor-specific promoters to exclusively activate gene expression in cancer cells are being investigated.

10.1.4 Metabolism and Degradation

The breakdown of the genetic material that is supplied to the cells is a complicated aspect of gene therapy metabolism. When host cells metabolize viral vectors carrying the therapeutic

gene, the vector is broken down by proteases, and the therapeutic gene is either produced as RNA or incorporated into the genome. A crucial component of gene therapy pharmacokinetics is gene expression; for therapeutic benefits to be achieved, the gene must be translated into RNA and transcribed into protein after it has been effectively delivered into the target cell. However, a number of variables, such as the host immunological response, integration effectiveness, and vector type, might affect the length of time and degree of gene expression.

Even though they are typically less immunogenic, non-viral vectors nonetheless have problems with the vector's own degradation. These vectors frequently experience lysosomal degradation once within the cell, and the cell's normal processes may digest or remove the therapeutic DNA or RNA. The effectiveness of genomic integration and the durability of the therapeutic gene can have a substantial impact on the long-term therapeutic results if the therapy is intended to integrate into the host genome. Additionally, some gene therapies use episomal delivery, in which the gene is expressed momentarily rather than integrated into the host genome, potentially leading to shorter therapeutic effect durations.

10.1.5 Elimination of Gene Therapies

The delivery vector and any unintegrated or non-expressed genetic material must be removed in order to eradicate gene treatments. Numerous processes, such as immune cell phagocytosis, urine excretion, or proteolytic breakdown, can cause this. The formulation and delivery mechanism can affect the half-life of the therapeutic gene, the vector, and any residual RNA or DNA fragments in the body. The body may recognize the viral vector as alien in certain situations and develop an immunological reaction, which causes the therapy to be cleared quickly. This is known as immune-mediated clearance. This immune reaction can have both positive and negative effects; it may aid in the removal of undesirable genetic material, but it may also lessen the therapy's efficacy, particularly if it is meant to be administered repeatedly or over an extended period of time.

The immune system's reaction, liver and kidney function, and the particular vector design are some of the variables that affect the systemic clearance of gene therapy. For instance, non-viral vectors may be cleaned more slowly, possibly leading to prolonged exposure in the body, whereas viral vectors may be removed by the liver and spleen's mononuclear phagocyte system (MPS). Therefore, a balance between effective delivery, prolonged gene expression, and controlled removal is necessary for the therapeutic impact to last.

10.5281/zenedo.15960797

10.1.6 Challenges in Gene Therapy Pharmacokinetics

The intricacy of gene therapy pharmacokinetic research presents a number of difficulties. These include problems like short-term gene expression, restricted tissue targeting, vector immunogenicity, and individual response variability. As gene therapies advance, new strategies are being created to enhance the pharmacokinetics. These strategies include ways to lessen immune responses that could compromise the therapy's efficacy, biodegradable carriers that can regulate the release of the therapeutic agent, and engineered vectors with improved targeting capabilities.

10.2IMMUNOTHERAPY AND VACCINES

Among the most promising therapeutic modalities in contemporary medicine are immunotherapy and vaccinations, especially for the treatment of autoimmune disorders, infections, and malignancies.



Figure 2: Immunotherapy

Although they accomplish this in different ways, both approaches seek to use the immune system's strength to combat illness. Immunotherapy is the process of modifying the immune system to either inhibit unwarranted immune responses or improve the immune system's capacity to identify and eliminate infections or tumor cells. By priming the immune system to identify and combat cancer cells [7], vaccines, on the other hand, work to boost the immune system beforehand and avoid infection by pathogens.

10.2.1 Immunotherapy: Types and Mechanisms

Immunotherapy has emerged as a cornerstone in the treatment of cancer, especially with the development of immune checkpoint inhibitors, monoclonal antibodies, and chimeric antigen receptor (CAR) T-cell therapies. These therapies work by stimulating or enhancing the immune system's ability to recognize and attack cancer cells, which may otherwise evade immune surveillance.

10.5281/zenedo.15960797

- **Immune Checkpoint Inhibitors**: The immune system's regulating processes known as immune checkpoints stops overreactions. These pathways are frequently used by tumors to evade immune detection. Immune checkpoint proteins like PD-1 and CTLA-4 are blocked by medications like nivolumab and pembrolizumab, which enables T cells to target cancer cells. certain medications help "release the brakes" on the immune system, enabling it to identify and eliminate cancer cells more efficiently, by blocking certain checkpoints.
- **Monoclonal Antibodies**: Lab-created molecules known as monoclonal antibodies (mAbs) have the ability to attach to certain targets on the surface of infections or cancer cells. For instance, the monoclonal antibody rituximab, which is used to treat lymphoma, attaches itself to B-cells' CD20 and marks them for elimination. Additionally, monoclonal antibodies can be used to encourage the immune system to attack cancer cells by attaching to immune system receptors (e.g., trastuzumab targeting HER2-positive breast cancer) or to deliver cytotoxic drugs directly to the target cells (known as antibody-drug conjugates).
- **CAR T-Cell Therapy**: A novel technique called chimeric antigen receptor (CAR) T-cell therapy involves genetically modifying a patient's T cells to express receptors that can identify antigens unique to malignancy. To target and eradicate cancer cells, the T cells are reintroduced into the patient after being altered and multiplied in the laboratory. Acute lymphoblastic leukemia and non-Hodgkin lymphoma are two blood malignancies that have responded remarkably well to CAR T-cell therapies like Kymriah and Yescarta.

Despite their promise, immunotherapies can also result in adverse effects due to the activation of the immune system. These include autoimmune reactions, cytokine release syndrome, and immune-related adverse events that affect various organs. Ongoing research aims to mitigate these risks while improving the efficacy of immunotherapies.

10.2.2 Vaccines: Preventive Immunization

Because they can prevent a variety of infectious diseases, vaccines have been one of the most effective public health treatments. The fundamental idea behind vaccinations is to introduce a pathogen in a harmless form to the immune system, such as bacterial proteins, inactivated viral particles, or fragments of DNA or RNA, which causes the immune system to mount an attack. Immunological memory is created as a result of this reaction, enabling the immune system to react quickly and efficiently in the event that the pathogen is encountered again.

10.5281/zenedo.15960797

- **Traditional Vaccines:** These include inactivated or weakened forms of the pathogen that stimulate an immune response without causing disease. For example, the polio vaccine and the measles, mumps, and rubella (MMR) vaccine use inactivated or attenuated viruses to train the immune system. These vaccines have played a central role in reducing the prevalence of infectious diseases globally.
- **Subunit, Recombinant, and Conjugate Vaccines:** Without presenting the entire pathogen, these vaccines can boost the immune system by including fragments of the pathogen, like proteins or carbohydrates. Subunit vaccinations include the HPV and hepatitis B vaccines, whereas pneumococcal conjugate vaccines attach bacterial sugars to proteins to boost immunogenicity, particularly in newborns.
- **mRNA Vaccines:** The advent of mRNA vaccines represents a major advancement in vaccination technology. Unlike traditional immunizations, mRNA vaccines use messenger RNA instead of live viral particles to instruct cells to produce a protein that mimics the pathogen. For example, the mRNA-based Moderna and Pfizer-BioNTech COVID-19 vaccines instruct cells to produce the spike protein of the SARS-CoV-2 virus. Following the recognition of this spike protein, the immune system initiates a response, preventing further infections.

One of the key challenges with vaccines is ensuring their global accessibility and overcoming issues such as vaccine hesitancy and logistical barriers in low-resource settings. Additionally, the development of universal vaccines, such as those targeting multiple strains of influenza or malaria, remains an area of intense research [8].

10.2.3 Cancer Vaccines: Preventive and Therapeutic Approaches

Cancer vaccines are an emerging area of immunotherapy aimed at stimulating the immune system to recognize and destroy cancer cells. There are two main types of cancer vaccines:

- **Preventive Cancer Vaccines**: By encouraging the immune system to identify and react to viral infections that are known to cause cancer, these vaccines aim to stop the development of cancer. For instance, the HPV vaccine aids in preventing human papillomavirus infections, which are connected to the emergence of cervical cancer. The Hepatitis B vaccine also guards against viral infections linked to liver cancer.
- **Therapeutic Cancer Vaccines**: By encouraging the immune system to seek out and eliminate cancer cells, these vaccinations are intended to cure malignancies that already exist. Sipuleucel-T is a therapeutic vaccine for prostate cancer that stimulates the

patient's dendritic cells to mount a strong defense against the cancer's cells. Other strategies, such as vaccines that target antigens unique to cancer, are being researched.

Despite their potential, cancer vaccines have problems with tumor heterogeneity, or the variation across cancer cells, and their capacity to elicit a robust and long-lasting immune response. Nonetheless, there is a great deal of promise for enhancing the effectiveness of cancer treatment when cancer vaccines are combined with other immunotherapies such checkpoint inhibitors or CAR T-cell therapy.

10.2.4 Adjuvants and Immune Modulation

The strategic application of adjuvants and immune modification is essential in the field of immunotherapy and vaccine development to increase the efficacy of treatments and vaccines. These methods are designed to improve the overall therapeutic outcome, particularly in difficult conditions like cancer and persistent infections, by strengthening the immune system's reaction to an antigen. These tactics can result in stronger and more durable immunity by boosting or adjusting immune responses.

- **Adjuvants: Enhancing Vaccine Efficacy**

Vaccines contain adjuvants to improve the immune response to the antigen, which is frequently inadequate when the antigen is administered alone. By encouraging a more robust and sustained immune response, an adjuvant added to a vaccination formulation can increase the vaccine's effectiveness. By stimulating the innate immune system, improving the antigen's presentation to immune cells, and increasing the pathogen's overall immunological recognition, adjuvants accomplish this.

- **Alum (Aluminum Salts)**: One of the most often utilized adjuvants in vaccines is alum. For many years, it has been a component in vaccines like the DTP (diphtheria, tetanus, and pertussis) vaccine. Alum functions by causing a depot to build at the injection site, from which the antigen is gradually released. This slow release lengthens immune system exposure and aids in triggering humoral and cellular immunological responses. Even though alum is used extensively, it is frequently thought to be less effective than more recent adjuvants, and research is still being done to find substitutes that might provide stronger immune activation.
- **MF59**: Fluad is one of the influenza vaccines that contains MF59, an oil-in-water emulsion adjuvant. By causing a local inflammatory reaction at the injection site, it improves dendritic cell antigen presentation and increases T cell activation, which

10.5281/zenedo.15960797

strengthens the immunological response. In older people, who frequently have weakened immune responses, MF59 can boost a vaccine's effectiveness. It has been demonstrated that the adjuvant lengthens the vaccine's duration of protection and increases antibody titers.

- **TLR Agonists**: A class of adjuvants known as toll-like receptor (TLR) agonists stimulates immune cells' pattern recognition receptors. The body's initial line of defense against infections is the innate immune system, which includes these receptors. These adjuvants improve the body's recognition and reaction to the vaccination antigen by activating TLRs, which sets off a series of immunological reactions. To improve humoral and cellular immunity, TLR agonists like CpG oligodeoxynucleotides (TLR9 agonist) and imiquimod (TLR7 agonist) are being researched in a variety of vaccine formulations. These adjuvants might be especially helpful in vaccinations that fight cancer and viral diseases.

➢ **Immune Modulation in Immunotherapy**

Immune modulation is the process of changing the activity of the immune system by using pharmaceuticals, either to decrease inappropriate immune activity (immune suppression) or to increase immunological responses (immune stimulation) [9]. These tactics are used in immunotherapy for both vaccinations and treatments to enhance results, especially in conditions like cancer, autoimmune disorders, and persistent infections.

- **Cytokine Therapies**: Cytokines are signaling proteins that mediate and regulate immune responses. Interleukins (such as IL-2, IL-12, and IL-15) and interferons (IFN-alpha, IFN-beta, and IFN-gamma) are examples of cytokines that have been used as immune-modulating agents in cancer immunotherapy and chronic viral infections. These cytokines can stimulate the proliferation and activation of T cells and natural killer (NK) cells, leading to improved immune surveillance and the elimination of cancer cells or infected cells.
    - Interleukin-2 (IL-2) has been used to treat cancers like renal cell carcinoma and melanoma. IL-2 stimulates the expansion of T cells, which enhances the immune system's ability to recognize and destroy tumor cells. However, high doses of IL-2 can cause severe side effects, such as capillary leak syndrome, leading to ongoing research focused on optimizing its delivery and reducing toxicity.

- Interferons play a significant role in both antiviral and anticancer treatments. Interferon-alpha is used in the treatment of hepatitis C and certain cancers such as hairy cell leukemia and melanoma, by boosting the cytotoxic activity of immune cells, particularly T lymphocytes and NK cells.

- Immune Checkpoint Modulators: Another aspect of immune modulation is the use of checkpoint inhibitors that reverse immune suppression within the tumor microenvironment. Checkpoint inhibitors such as nivolumab and pembrolizumab block inhibitory receptors like PD-1 on T cells, enhancing T-cell-mediated destruction of tumor cells. These inhibitors are now widely used in cancers like non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma, marking significant improvements in patient survival rates.
- Immune Suppressants in Autoimmune Diseases: In autoimmune diseases, the immune system mistakenly attacks the body's own cells. Drugs that modulate immune responses, such as immune suppressants (e.g., methotrexate, cyclophosphamide, and cyclosporine), are used to suppress the overactive immune system. These agents work by inhibiting the activation and proliferation of immune cells such as T cells and B cells, thereby reducing inflammation and tissue damage. However, immune suppression increases the risk of infection and malignancy, and as such, precise modulation of immune responses is a key area of research.

➢ **Future Directions: Combination Strategies**

The combination of adjuvants and immune modification in immunotherapy and vaccine development is one of the most promising future prospects. For instance, in cancer treatment, a synergistic benefit may be provided by combining immune checkpoint inhibitors that increase T-cell activity with adjuvants that activate the innate immune system. Clinical trials for a number of diseases are already looking into this combo approach, which aims to overcome the immunosuppressive milieu frequently found in tumors and boost a more robust immune response.

Combining adjuvants and immune modulators in the context of infectious disease vaccines may also enhance the immune response to vaccinations, especially for pathogens like HIV and malaria that have difficult immune evasion mechanisms. In populations at high risk of infection, broader, longer-lasting immunity might be achievable by maximizing the interaction between vaccine ingredients, adjuvants, and immune modulators.

10.2.5 Future Directions in Immunotherapy and Vaccines

Personalized medicine, where therapies are customized to the patient's genetic composition and the unique features of the disease, holds the key to the future of immunotherapy and vaccinations. Biomarker-driven methods are anticipated to be used in immunotherapy to determine which patients are most likely to benefit from immune checkpoint inhibitors or CAR T-cell therapies. The creation of universal vaccinations against diseases like HIV and influenza is a continuous priority in the vaccine industry.

More effective and focused treatments are also possible with the incorporation of gene-editing and nanotechnology (e.g., CRISPR-Cas9) into vaccination and immunotherapy development. It is anticipated that the combination of vaccinations, immunotherapies, and targeted medicines would result in more individualized, less harmful, and more successful treatment choices for a variety of illnesses, including cancer and infections.

10.3 OLIGONUCLEOTIDES AND OTHER BIOTECH PRODUCTS

A significant class of biotech products known as oligonucleotides has transformed molecular medicine, especially in the fields of genetic research, diagnostics, and treatment. Usually consisting of 20 to 50 nucleotides [10], these brief, single-stranded or double-stranded DNA or RNA molecules are employed for a variety of reasons, such as gene editing, gene silencing, and as therapeutic agents in the treatment of genetic illnesses.



Figure 3: Oligonucleotides

Oligonucleotides are indispensable tools in biotechnology because of their exceptional capacity to target particular genetic sequences in cells.

10.5281/zenedo.15960797

10.3.1 Types of Oligonucleotides

Oligonucleotides can be classified based on their function, structure, and the techniques they employ in therapy or research. These include antisense oligonucleotides, RNA interference (RNAi) oligonucleotides, aptamers, and gene-editing oligonucleotides.

- **Antisense Oligonucleotides (ASOs)**: By attaching themselves to particular messenger RNA (mRNA) molecules, these oligonucleotides stop the associated gene from being translated into a protein. This kind of action is especially helpful for mutating genes that cause illnesses. An antisense oligonucleotide called nusinersen, for instance, is used to treat spinal muscular atrophy by encouraging a mutant gene to produce a functioning SMN protein. ASOs are a viable treatment approach for a variety of genetic illnesses because they can restore gene expression by attaching to the mRNA and altering its splicing.
- **RNA Interference (RNAi) Oligonucleotides**: short RNA molecules, such microRNA (miRNA) or short interfering RNA (siRNA), target mRNA for degradation in RNA interference (RNAi), a natural mechanism that inhibits the expression of particular genes. Synthetic siRNAs are employed in RNAi-based treatments to inhibit the expression of genes that cause disease. Numerous applications, including as cancer, viral infections, and hereditary illnesses, have investigated this strategy. The main benefit of RNAi-based medicines is their ability to precisely silence particular genes, which makes them an effective treatment option for illnesses brought on by overactive genes.
- **Aptamers**: Short, single-stranded oligonucleotides (DNA or RNA) known as aptamers have a high affinity and selectivity for binding to particular proteins or other compounds. Aptamers work similarly to antibodies, although they are easier to synthesize and have greater chemical stability. These oligonucleotides can be used in diagnostics, targeted therapy, and drug delivery. Pegaptanib, for instance, is an aptamer-based medication that inhibits vascular endothelial growth factor (VEGF), a protein that causes aberrant blood vessel formation in the eye, in order to treat age-related macular degeneration.
- **Gene-Editing Oligonucleotides**: Utilizing oligonucleotides has also been essential to the development of gene-editing systems like CRISPR-Cas9. The Cas9 protein is guided by these oligonucleotides to make precise cuts in the DNA at particular sites. The genetic code can then be changed by the system by adding or removing particular

10.5281/zenedo.15960797

genetic material. By fixing DNA mutations, this method has enormous potential for curing genetic illnesses.

10.3.2 Therapeutic Applications of Oligonucleotides

The development of oligonucleotide-based therapeutics has been a significant advancement in biotechnology [11], offering new avenues for the treatment of diseases that were previously considered untreatable, especially genetic disorders and certain cancers.

- **Genetic Disorders**: Antisense oligonucleotides (ASOs) and RNA interference (RNAi) therapies are two examples of oligonucleotide-based therapeutics that have demonstrated encouraging outcomes in the treatment of genetic illnesses brought on by gene mutations. For example, ASO-based medications eteplirsen (Exondys 51) and nusinersen (Spinraza) are authorized to treat Duchenne muscular dystrophy and spinal muscular atrophy, respectively. These treatments enhance patient outcomes by fixing the underlying genetic mutations. Additional oligonucleotide treatments are being developed for amyotrophic lateral sclerosis (ALS), Huntington's disease, and cystic fibrosis.
- **Cancer Therapy**: Additionally, oligonucleotides are being investigated as treatments for a number of malignancies. Genes implicated in tumor growth and metastasis can be silenced by siRNA and ASO molecules. For instance, clinical trials are being conducted to examine oligonucleotide-based inhibitors that target oncogenes like p53 and KRAS. Aptamers that attach to tumor markers and stop the growth of cancer cells are also being developed as targeted cancer therapies. Additionally, oligonucleotides can be employed to improve the efficacy of cancer immunotherapies by modifying the immune system.
- **Viral Infections**: By inhibiting particular viral genes required for replication, antiviral oligonucleotides—especially those based on RNA interference—have demonstrated promise in the treatment of viral infections. Oligonucleotide-based treatments have been investigated for viral illnesses such as hepatitis B, hepatitis C, and HIV. One possible future therapeutic approach is the use of siRNA to stop the HIV-1 virus from replicating. A potent tool in antiviral therapy, particularly for viruses with high mutation rates, is the capacity to target viral RNA with high specificity.

10.3.3 Challenges and Future Directions

While the therapeutic potential of oligonucleotides is vast, several challenges must be overcome for these products to achieve widespread clinical success. Some of the key challenges include:

- **Delivery**: In the circulation, oligonucleotides—particularly siRNA and antisense molecules—are usually fragile and susceptible to quick nuclease degradation. For them to be effective, they must be delivered to the target tissue efficiently. To prevent oligonucleotides from degrading and to improve cellular uptake, researchers are creating novel delivery mechanisms such viral vectors, polymeric carriers, and lipid nanoparticles.
- **Immunogenicity**: An immunological reaction may be triggered when synthetic oligonucleotides are introduced into the body. Despite being less immunogenic than viral vectors, non-viral delivery techniques can nevertheless be recognized and attacked by the immune system. This may result in adverse effects and lessen the treatment's therapeutic efficiency. There are continuous attempts to chemically alter oligonucleotides in order to improve stability and lower immunological activation.
- **Cost and Manufacturing**: Manufacturing oligonucleotide-based treatments can be costly, especially when significant amounts of highly pure components are involved. These treatments may be prohibitively expensive because to the intricacy of the synthesis process and the requirement for strict quality control. Efforts to lower expenses and expedite production procedures will be essential as research advances in order to make these treatments available to a larger patient base.

The prospects for oligonucleotide-based treatments appear bright in spite of these obstacles. Many present constraints should be addressed by ongoing developments in bioinformatics, nanotechnology, and genetic engineering. The accuracy and efficacy of oligonucleotide-based therapeutics will be improved by ongoing research into novel chemical modifications and delivery systems, enabling more specialized and less harmful treatments [12].

10.3.4 Other Biotech Products

Beyond oligonucleotides, several other biotech products are currently in use or under development in the field of biotechnology. These products include monoclonal antibodies, recombinant proteins, cell-based therapies, and biosimilars, each contributing to advancements in the treatment of complex diseases.

- **Monoclonal Antibodies (mAbs)**: These antibodies are made to attach to particular cell antigens, neutralizing infections or designating cells for immune system destruction. Cancer, autoimmune disorders, and infectious diseases are among the conditions that are treated with monoclonal antibodies. For instance, trastuzumab is used to treat HER2-positive breast cancer, and rituximab is used to treat non-Hodgkin lymphoma.
- **Recombinant Proteins**: Therapeutic proteins are produced using recombinant DNA technology. These consist of growth factors like erythropoietin, clotting factors for hemophilia, and hormones like insulin. The therapy of many diseases, especially endocrine and metabolic conditions, has been transformed by the creation of recombinant proteins.
- **Cell-Based Therapies**: This includes treatments that include cell transplantation, such stem cell therapy, which is being investigated to treat a number of illnesses, such as diabetes, heart disease, and neurological diseases. A major advancement in oncology has been CAR-T cell therapy, which entails altering a patient's own immune cells to target cancer cells.

10.4 PHARMACODYNAMICS OF BIOTECHNOLOGY DRUGS

The study of how medications affect the body, including their methods of action, the connection between concentration and effect, and the variables affecting their safety and effectiveness, is known as pharmacodynamics. Pharmacodynamics is especially complicated in the context of biotechnology pharmaceuticals because these products are usually created by biotechnological procedures or derived from live organisms [13]. The target biological system, the drug's molecular structure, and its intended therapeutic use all affect the pharmacodynamics of biotechnology medications. Biotechnology medications like monoclonal antibodies, gene therapies, and recombinant proteins provide more focused and specialized treatments, frequently with unique mechanisms of action, in contrast to conventional small-molecule medications, which usually function by attaching to enzymes or receptors to produce their effects.

10.4.1 Mechanisms of Action of Biotechnology Drugs

Biotechnology drugs function through a variety of mechanisms, often acting on highly specific targets such as proteins, receptors, or genes [14]. The targeted nature of these drugs allows for more precise therapeutic effects and the potential to minimize unwanted side effects.

- **Monoclonal Antibodies (mAbs)**: Monoclonal antibodies are made to specifically target antigens, which are typically found on the surface of immune cells, infections, or cancer cells. Once the antibody attaches itself to its target, it can either cause the immune system to attack the target cell or stop the antigen's action (for example, a growth factor receptor in cancer). For instance, in non-Hodgkin lymphoma, rituximab targets CD20 on B cells, causing these malignant cells to be destroyed. Trastuzumab (Herceptin) and other monoclonal antibodies block the development of breast cancer cells by targeting the HER2 receptor.
- **Recombinant Proteins**: Treatments for blood abnormalities, hormone deficits, and metabolic diseases sometimes involve the use of recombinant proteins, such as insulin, growth factors, or hormones. These medications work by imitating or boosting the action of proteins found in nature. For example, in patients with anemia, recombinant erythropoietin promotes the generation of red blood cells, while in patients with diabetes, recombinant insulin aids in blood glucose regulation.
- **Gene Therapy**: In order to replace or fix defective genes that cause a disease, gene treatments include inserting genetic material into the patient's cells. Gene therapy can fix DNA mutations, alter the patient's immune system, or replace a missing or damaged protein. For instance, gene therapy helps motor neurons that have spinal muscular atrophy manufacture the SMN protein, which is essential for muscle function, by giving them a functional copy of the SMN1 gene. In order to treat a range of hereditary illnesses, gene therapies can also be employed to alter how specific genes are expressed.
- **RNA-Based Therapies**: Small interfering RNA (siRNA) and antisense oligonucleotides are examples of RNA-based treatments that work by focusing on particular RNA molecules to stop the synthesis of toxic proteins. Messenger RNA (mRNA) can be bound by antisense oligonucleotides, which stop it from being translated into proteins. Nusinersen is an antisense oligonucleotide that increases the generation of functional SMN protein by altering the splicing of the SMN2 gene in spinal muscular atrophy.

10.4.2 Target Specificity and Selectivity

The capacity of biotechnology medications to precisely target a single biological route or receptor enhances their accuracy and minimizes off-target effects, making this one of their most important benefits. Small molecules, on the other hand, frequently have wider impacts and have the ability to interact with several different bodily targets, which may result in adverse

effects. In order to provide a more targeted therapeutic impact, biotechnology medications are usually made to interact with one or a small number of targets [15].

For instance, monoclonal antibodies called immune checkpoint inhibitors, like pembrolizumab (Keytruda), are made to prevent T cells from recognizing and attacking cancer cells by blocking their PD-1 receptor. By specifically targeting immunological checkpoint pathways, the immune system's capacity to combat cancer is strengthened while the harm to healthy tissues is reduced. Similarly, because they prevent the formation of blood arteries that nourish tumors, monoclonal antibodies that target VEGF (vascular endothelial growth factor) are used to treat a variety of malignancies.

Even while these focused treatments have a lot of promise, there are drawbacks. Immunogenicity is a major problem, where the body's immune system produces an immunological reaction to the biologic medicine because it perceives it as a foreign substance. This immunological reaction may neutralize the medication, lessen its potency, or result in undesirable side effects. Patients who get monoclonal antibodies, for example, may produce antibodies against the therapeutic antibodies, which could result in adverse responses or decreased efficacy. Biologics' immunogenic profile is being improved, and methods to increase the precision of their targeting are being developed.

10.4.3 Dose-Response Relationship and Efficacy

One crucial component of the pharmacodynamics of biotechnology medications is the dose-response relationship. Determining the ideal dosage and frequency of administration for these medications requires an understanding of the connection between drug concentration and therapeutic impact [16].



Figure 4: Dose-Response Relationship

Biologic medications frequently have a smaller therapeutic window than small-molecule medications, when the medication is both safe and efficacious[17].

For instance, getting enough of the medication in the bloodstream to bind to the target antigen and have a therapeutic impact is frequently necessary for monoclonal antibodies to be effective. However, going over the recommended dosage could result in toxicities, immunological responses, or problems associated to the infusion. As a result, depending on variables such patient characteristics, the course of the disease, and the existence of antibodies that could neutralize the medication, dose modifications might be required.

In a similar vein, gene therapies frequently call for close observation of the dosage and the body's dispersion of the therapeutic genetic material. Overexpression of the therapeutic protein or immunological reactions are examples of unforeseen outcomes that could result from introducing too much genetic material. Conversely, insufficient therapeutic results could arise from using too little of the gene therapy product.

10.4.4 Pharmacodynamic Interactions and Side Effects

Drugs used in biotechnology may also interact pharmacodynamically with other pharmaceuticals. These interactions may result in new, unexpected side effects or improve or decrease the drug's effectiveness[18]. For example, monoclonal antibodies may have antagonistic or synergistic effects on immune regulation and tumor response when administered in conjunction with chemotherapy or other immunological treatments. Biologics should be continuously watched for side effects, such as cytokine release syndrome (CRS) or immune-related adverse events, which can occur when combined with other treatments.

Furthermore, an overzealous immune response brought on by certain biotechnology medications, especially those that alter the immune system, may result in tissue damage or autoimmune reactions. Immunocheckpoint inhibitors, for instance, can be useful in the treatment of cancer, but they can also result in immune-related side effects including dermatitis, colitis, or hepatitis since they make the immune system more hostile to targeting healthy tissues in addition to the tumor[19].

Because of the complexity of these interactions, monitoring the pharmacodynamics of biotechnology pharmaceuticals entails evaluating not only the therapeutic benefits of the treatment but also the possible hazards related to adverse events, drug interactions, and immunological modification. This emphasizes the value of personalized medicine strategies,

in which treatment plans are customized according to each patient's unique pharmacological reaction and tolerance.

10.4.5 Future Directions in Pharmacodynamics of Biotechnology Drugs

The ongoing development of precision medicine holds the key to the future of pharmacodynamics in biotechnology pharmaceuticals. Designing more tailored biologics that increase efficacy while lowering adverse effects will be feasible with a better understanding of genetic, molecular, and cellular pathways. Healthcare professionals will be able to maximize the use of biotechnology medications for specific patients, guaranteeing greater results, thanks to customized dose plans, enhanced delivery methods, and developments in monitoring and diagnostics[20].

Furthermore, new technologies like bispecific antibodies, CAR-T cell treatments, and gene editing (e.g., CRISPR/Cas9) have the potential to improve the specificity and accuracy of biotechnology medications, providing safer and more effective treatment choices for a variety of illnesses.

10.5281/zenedo.15960797

BIBLIOGRAPHY

1. Roohullah, A., Ganju, V., Zhang, F., Zhang, L., Yu, T., Wilkinson, K., ... & de Souza, P. (2021). First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.
2. Saadeddin, A., Purohit, V., Huh, Y., Wong, M., Maulny, A., Dowty, M. E., & Sagawa, K. (2024). Virtual bioequivalence assessment of Ritlecitinib capsules with incorporation of observed clinical variability using a physiologically based pharmacokinetic model. *The AAPS Journal*, *26*(1), 17.
3. Sakagami, M. (2020). In vitro, ex vivo and in vivo methods of lung absorption for inhaled drugs. *Advanced drug delivery reviews*, *161*, 63-74.
4. Salunke, S., O'Brien, F., Tan, D. C. T., Harris, D., Math, M. C., Ariën, T., ... & Timpe, C. (2022). Oral drug delivery strategies for development of poorly water-soluble drugs in paediatric patient population. *Advanced Drug Delivery Reviews*, *190*, 114507.
5. Samineni, R., Chimakurthy, J., & Konidala, S. (2022). Emerging role of biopharmaceutical classification and biopharmaceutical drug disposition system in dosage form development: A systematic review. *Turkish journal of pharmaceutical sciences*, *19*(6), 706.
6. Scioli Montoto, S., Muraca, G., & Ruiz, M. E. (2020). Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects. *Frontiers in molecular biosciences*, *7*, 587997.
7. Shi, M., Sun, J., Zhou, J., Yu, H., Yu, S., Xia, G., ... & Shen, Y. (2018). Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies. *Investigational New Drugs*, *36*, 269-277.
8. Shiraishi, K., & Yokoyama, M. (2019). Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review. *Science and technology of advanced materials*, *20*(1), 324-336.
9. Shukla, S., Singh, B., Singh, A., & Singh, C. (2022). Emerging and advanced drug delivery systems for improved biopharmaceutical attributes of gallic acid: A review. *Phytomedicine Plus*, *2*(4), 100369.

10. Siemons, M., Schroyen, B., Darville, N., & Goyal, N. (2023). Role of modeling and simulation in preclinical and clinical long-acting injectable drug development. *The AAPS Journal*, *25*(6), 99.
11. Song, D., & Jusko, W. J. (2021). Across-species meta-analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches. *Biopharmaceutics & drug disposition*, *42*(5), 191-203.
12. Souza, T. S., Moreira, D. R. M., & Marcelino, H. R. (2022). Chemical and pharmacological properties of decoquinate: A review of its pharmaceutical potential and future perspectives. *Pharmaceutics*, *14*(7), 1383.
13. Stillhart, C., Asteriadis, A., Bocharova, E., Eksteen, G., Harder, F., Kusch, J., ... & Reppas, C. (2023). The impact of advanced age on gastrointestinal characteristics that are relevant to oral drug absorption: An AGePOP review. *European Journal of Pharmaceutical Sciences*, *187*, 106452.
14. Subbaiah, M. A., Rautio, J., & Meanwell, N. A. (2024). Prodrugs as empowering tools in drug discovery and development: Recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates. *Chemical Society Reviews*, *53*(4), 2099-2210.
15. Talevi, A., & Quiroga, P. A. (2018). ADME processes in pharmaceutical sciences. *Switzerland: Springer*.
16. Tambe, V., Pande, S., Gadeval, A., Rajpoot, K., Raval, N., & Tekade, R. K. (2021). Microdialysis: an emerging technique for pharmacokinetic–pharmacodynamic profiling. In *Biopharmaceutics and Pharmacokinetics Considerations* (pp. 601-616). Academic Press.
17. Tekade, R. K. (2021). *Biopharmaceutics and Pharmacokinetics Considerations*. Academic Press.
18. Tekade, R. K. (Ed.). (2022). *Pharmacokinetics and Toxicokinetic Considerations-Vol II* (Vol. 2). Academic Press.
19. Telange, D. R., Sohail, N. K., Hemke, A. T., Kharkar, P. S., & Pethe, A. M. (2021). Phospholipid complex-loaded self-assembled phytosomal soft nanoparticles: evidence of enhanced solubility, dissolution rate, ex vivo permeability, oral bioavailability, and antioxidant potential of mangiferin. *Drug Delivery and Translational Research*, *11*, 1056-1083.